Thomas Soloway
Director/Board Member at THIRD HARMONIC BIO, INC.
Thomas Soloway active positions
Companies | Position | Start | End |
---|---|---|---|
THIRD HARMONIC BIO, INC. | Director/Board Member | 30/06/2022 | - |
Independent Dir/Board Member | 30/06/2022 | - | |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Chief Executive Officer | 18/01/2021 | - |
T-Knife Therapeutics, Inc. | Chief Executive Officer | - | - |
Career history of Thomas Soloway
Former positions of Thomas Soloway
Companies | Position | Start | End |
---|---|---|---|
SATSUMA PHARMACEUTICALS, INC. | Director/Board Member | 01/07/2020 | 07/06/2023 |
Independent Dir/Board Member | 01/07/2020 | 07/06/2023 | |
ASCENDIS PHARMA A/S | Director of Finance/CFO | 31/12/2013 | 31/08/2015 |
Investor Relations Contact | 31/12/2013 | 31/01/2019 | |
Public Communications Contact | 31/12/2013 | 31/01/2019 | |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Comptroller/Controller/Auditor | 31/01/2009 | 06/05/2012 |
Chief Operating Officer | 31/01/2009 | 30/11/2013 | |
Director of Finance/CFO | 31/01/2009 | 06/05/2012 | |
Founder | 31/12/2001 | 30/11/2013 | |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Director/Board Member | 29/01/2009 | 05/02/2009 |
Montreux Equity Partners, Inc.
Montreux Equity Partners, Inc. Investment ManagersFinance Montreux Equity Partners, Inc. (Montreux Equity Partners) is a Venture Capital firm founded in 1993 by Dan K. Turner. The firm is headquartered in San Francisco, California. | Corporate Officer/Principal | 31/12/1992 | - |
AUDENTES THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 28/09/2015 | 14/01/2020 |
Chief Operating Officer | - | - | |
Director of Finance/CFO | 28/09/2015 | - | |
Treasurer | 14/01/2020 | - | |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
Training of Thomas Soloway
University of Southern California | Undergraduate Degree |
Georgetown University | Masters Business Admin |
Statistics
International
United States | 11 |
Denmark | 2 |
Germany | 2 |
Operational
Chief Operating Officer | 3 |
Director of Finance/CFO | 3 |
Director/Board Member | 3 |
Sectoral
Health Technology | 9 |
Consumer Services | 3 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
ASCENDIS PHARMA A/S | Health Technology |
PARATEK PHARMACEUTICALS, INC. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
Private companies | 7 |
---|---|
Montreux Equity Partners, Inc.
Montreux Equity Partners, Inc. Investment ManagersFinance Montreux Equity Partners, Inc. (Montreux Equity Partners) is a Venture Capital firm founded in 1993 by Dan K. Turner. The firm is headquartered in San Francisco, California. | Finance |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Transcept Pharma, Inc.
Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Health Technology |
T-Knife Therapeutics, Inc. |
- Stock Market
- Insiders
- Thomas Soloway
- Experience